Needham initiated coverage of Oculis (OCS) with a Buy rating and $36 price target Lead-asset OCS-01 aims to be the first non-invasive therapy for diabetic macular edema, while OCS-02 offers a biologic mechanism of action for dry-eye disease via eye drop, notes the analyst, who calls Oculis “an under-the-radar story nearing a data-rich period in early-2026.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Nvidia reportedly stops H20 AI chip output for China: Morning Buzz
- Oculis price target raised to $33 from $32 at H.C. Wainwright
- Oculis Holding: Buy Rating Backed by Strong Financials and Promising Clinical Pipeline
- Oculis Holding AG Reports Q2 2025 Financial Progress
- Oculis Holding Reports Strong Financial Position in Mid-2025